Online inquiry

IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2706MR)

This product GTTS-WQ2706MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD19&CD3E gene. The antibody can be applied in Diffuse Large B Cell Lymphoma (DLBCL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Mus musculus
RefSeq NM_001178098.2; NM_000733.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930; 916
UniProt ID P15391; P07766
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2706MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12037MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ14159MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA aIL6R88
GTTS-WQ1818MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ7835MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ7182MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ3632MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ12851MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OPN-305
GTTS-WQ6018MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO 1275
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW